☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Nevada
|
20-1176000
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
3360 Martin Farm Road, Suite 100
Suwanee, GA
|
30024
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
Common Stock, par value $0.001
|
SNWV
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
|
Non-accelerated filer ☒
|
Smaller reporting company ☒
|
|
Emerging growth company ☐
|
Page
|
||
PART I – FINANCIAL INFORMATION
|
||
Item 1.
|
4
|
|
4
|
||
5
|
||
6
|
||
7
|
||
8
|
||
Item 2.
|
20
|
|
Item 3.
|
24
|
|
Item 4.
|
24
|
|
PART II – OTHER INFORMATION
|
||
Item 1.
|
26
|
|
Item 1A.
|
26
|
|
Item 2.
|
26
|
|
Item 3.
|
26
|
|
Item 4.
|
26
|
|
Item 5.
|
26
|
|
Item 6.
|
27
|
|
28 |
ITEM 1. |
March 31, 2021
|
December 31, 2020
|
|||||||
ASSETS
|
||||||||
Current Assets:
|
||||||||
Cash
|
$
|
96
|
$
|
2,437
|
||||
Accounts receivable, net of allowance for doubtful accounts of $475 in 2021 and $343 in 2020
|
1,727
|
2,356
|
||||||
Inventory
|
2,935
|
2,956
|
||||||
Prepaid expenses and other current assets
|
405
|
179
|
||||||
Total Current Assets
|
5,163
|
7,928
|
||||||
Property and Equipment, net
|
531
|
471
|
||||||
Right of Use Assets, net
|
685
|
795
|
||||||
Other Intangible Assets, net
|
6,369
|
6,545
|
||||||
Goodwill
|
7,260
|
7,260
|
||||||
Other Assets
|
271
|
28
|
||||||
Total Assets
|
$
|
20,279
|
$
|
23,027
|
||||
LIABILITIES
|
||||||||
Current Liabilities:
|
||||||||
Senior secured promissory note payable, in default
|
$
|
10,903
|
$
|
10,676
|
||||
Convertible promissory notes payable, in default
|
4,000
|
4,000
|
||||||
Convertible promissory notes, related parties, in default
|
1,596
|
1,596
|
||||||
Accounts payable
|
5,728
|
4,454
|
||||||
Accrued expenses
|
2,492
|
2,127
|
||||||
Accrued employee compensation
|
2,463
|
2,541
|
||||||
Warrant liability
|
6,191
|
8,855
|
||||||
Current portion of SBA loans
|
464
|
321
|
||||||
Accrued interest
|
981
|
1,021
|
||||||
Accrued interest, related parties
|
124
|
77
|
||||||
Current portion of lease liabilities
|
414
|
451
|
||||||
Current portion of contract liabilities
|
32
|
32
|
||||||
Other
|
-
|
23
|
||||||
Total Current Liabilities
|
35,388
|
36,174
|
||||||
Non-current Liabilities
|
||||||||
SBA loans
|
1,033
|
143
|
||||||
Lease liabilities
|
319
|
391
|
||||||
Contract liabilities
|
156
|
37
|
||||||
Deferred tax liability
|
16
|
-
|
||||||
Total Non-currrent Liabilities
|
1,524
|
571
|
||||||
Total Liabilities
|
36,912
|
36,745
|
||||||
Contingencies
|
||||||||
STOCKHOLDERS’ DEFICIT
|
||||||||
Preferred Stock, par value $0.001, 5,000,000 shares authorized; 6,175, 293, 90 and 8 shares designated Series A, Series B, Series C and Series D, respectively; no shares issued and
outstanding at March 31, 2021 and December 31, 2020
|
-
|
-
|
||||||
Common Stock, par value $0.001, 800,000,000 shares authorized; 481,619,621 and 470,694,621 issued and outstanding at March 31, 2021 and December 31, 2020, respectively
|
482
|
471
|
||||||
Additional Paid-in Capital
|
144,582
|
142,563
|
||||||
Accumulated Deficit
|
(161,627
|
)
|
(156,690
|
)
|
||||
Accumulated Other Comprehensive Loss
|
(70
|
)
|
(62
|
)
|
||||
Total Stockholders’ Deficit
|
(16,633
|
)
|
(13,718
|
)
|
||||
Total Liabilities and Stockholders’ Deficit
|
$
|
20,279
|
$
|
23,027
|
Three Months Ended March 31,
|
||||||||
2021
|
2020
|
|||||||
Revenues:
|
||||||||
Product
|
$
|
253
|
$
|
75
|
||||
Accessory and parts revenue
|
1,825
|
63
|
||||||
License fees and other
|
38
|
11
|
||||||
Total Revenues
|
2,116
|
149
|
||||||
Cost of Revenues
|
1,055
|
130
|
||||||
|
||||||||
Gross Margin
|
1,061
|
19
|
||||||
Operating Expenses:
|
||||||||
Research and development
|
354
|
287
|
||||||
Selling and marketing
|
1,780
|
608
|
||||||
General and administrative
|
3,321
|
1,920
|
||||||
Total Operating Expenses
|
5,455
|
2,815
|
||||||
Operating Loss
|
(4,394
|
)
|
(2,796
|
)
|
||||
Other Income (Expense), net
|
||||||||
Change in fair value of warrant liability
|
635
|
-
|
||||||
Interest expense
|
(1,122
|
)
|
(19
|
)
|
||||
Interest expense, related party
|
(47
|
)
|
(183
|
)
|
||||
Loss on foreign currency exchange
|
7
|
(4
|
)
|
|||||
Other Income (Expense), net
|
(527
|
)
|
(206
|
)
|
||||
Net Loss before Income Taxes
|
(4,921
|
)
|
(3,002
|
)
|
||||
Provision for Income Taxes
|
16
|
-
|
||||||
Net Loss
|
(4,937
|
)
|
(3,002
|
)
|
||||
Other Comprehensive Loss
|
||||||||
Foreign currency translation adjustments
|
(8
|
)
|
5
|
|||||
Total Comprehensive Loss
|
$
|
(4,945
|
)
|
$
|
(2,997
|
)
|
||
Loss per Share:
|
||||||||
Net loss per share, basic and diluted
|
$
|
(0.01
|
)
|
$
|
(0.01
|
)
|
||
Weighted average shares outstanding, basic and diluted
|
518,490,225
|
296,061,866
|
Preferred Stock
|
Common Stock
|
|||||||||||||||||||||||||||||||
Number of
Shares
Issued and
Outstanding
|
Par Value
|
Number of
Shares
Issued and
Outstanding
|
Par Value
|
Additional Paid-
in Capital
|
Accumulated
Deficit
|
Accumulated
Other
Comprehensive
Loss
|
Total
|
|||||||||||||||||||||||||
Balances as of December 31, 2020
|
-
|
$
|
-
|
470,694,621
|
$
|
471
|
$
|
142,563
|
$
|
(156,690
|
)
|
$
|
(62
|
)
|
$
|
(13,718
|
)
|
|||||||||||||||
Cashless warrant exercise
|
-
|
-
|
10,925,000
|
11
|
(11
|
)
|
-
|
-
|
- | |||||||||||||||||||||||
Reclassification of warrant liability due to cashless warrant exercise
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2,030
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2,030 | |||
Net loss
|
-
|
-
|
-
|
-
|
-
|
(4,937
|
)
|
-
|
(4,937
|
)
|
||||||||||||||||||||||
Foreign currency translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
(8
|
)
|
(8
|
)
|
||||||||||||||||||||||
Balances as of March 31, 2021
|
-
|
$
|
-
|
481,619,621
|
$
|
482
|
$
|
144,582
|
$
|
(161,627
|
)
|
$
|
(70
|
)
|
$
|
(16,633
|
)
|
|||||||||||||||
-
|
||||||||||||||||||||||||||||||||
Balances as of December 31, 2019
|
-
|
$
|
-
|
293,780,400
|
$
|
294
|
$
|
115,458
|
$
|
(125,752
|
)
|
$
|
(62
|
)
|
$
|
(10,062
|
)
|
|||||||||||||||
Proceeds from warrant exercise
|
-
|
-
|
1,000,000
|
1
|
9
|
-
|
-
|
10
|
||||||||||||||||||||||||
Shares issued for services
|
-
|
-
|
1,000,000
|
1
|
199
|
-
|
-
|
200
|
||||||||||||||||||||||||
Stock-based compensation
|
-
|
-
|
-
|
-
|
21
|
-
|
-
|
21
|
||||||||||||||||||||||||
Conversion of short term notes
|
-
|
-
|
1,820,461
|
2
|
262
|
-
|
-
|
264
|
||||||||||||||||||||||||
Conversion of advances from related parties
|
-
|
-
|
62,811
|
-
|
3
|
-
|
-
|
3
|
||||||||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
(3,002
|
)
|
-
|
(3,002
|
)
|
||||||||||||||||||||||
Foreign currency translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
4
|
4
|
||||||||||||||||||||||||
Balances as of March 31, 2020
|
-
|
$
|
-
|
297,663,672
|
$
|
298
|
$
|
115,952
|
$
|
(128,754
|
)
|
$
|
(58
|
)
|
$
|
(12,562
|
)
|
Three Months Ended March 31,
|
||||||||
2021
|
2020
|
|||||||
Cash Flows - Operating Acivities:
|
||||||||
Net loss
|
$
|
(4,937
|
)
|
$
|
(3,002
|
)
|
||
Adjustments to reconcile net loss to net cash used by operating activities
|
||||||||
Amortization of intangibles
|
176
|
-
|
||||||
Depreciation
|
94
|
53
|
||||||
Bad debt expense
|
132
|
83
|
||||||
Share-based payment
|
-
|
222
|
||||||
Deferred taxes
|
16
|
-
|
||||||
Change in warrant valuation
|
(635
|
)
|
-
|
|||||
Amortization of debt issuance costs and original issue discount
|
228
|
-
|
||||||
Accrued interest
|
(40
|
)
|
2
|
|||||
Interest payable, related parties
|
47
|
183
|
||||||
Changes in operating assets and liabilities
|
||||||||
Accounts receivable - trade
|
489
|
(111
|
)
|
|||||
Inventory
|
21
|
24
|
||||||
Prepaid expenses
|
(444
|
)
|
(104
|
)
|
||||
Other assets
|
(24
|
)
|
(1
|
)
|
||||
Operating leases
|
(6
|
)
|
(3
|
)
|
||||
Accounts payable
|
1,274
|
(323
|
)
|
|||||
Accrued expenses
|
365
|
65
|
||||||
Accrued employee compensation
|
(78
|
)
|
289
|
|||||
Contract liabilties
|
(22
|
)
|
(23
|
)
|
||||
Net Cash Used by Operating Activities
|
(3,344
|
)
|
(2,646
|
)
|
||||
Cash Flows - Investing Activities
|
||||||||
Purchases of property and equipment
|
(101
|
)
|
(5
|
)
|
||||
Net Cash Flows Used by Investing Activities
|
(101
|
)
|
(5
|
)
|
||||
Cash Flows - Financing Activities
|
||||||||
Proceeds from sale of convertible preferred stock
|
-
|
2,250
|
||||||
Proceeds from SBA loan
|
1,033
|
-
|
||||||
Proceeds from warrant exercises
|
-
|
10
|
||||||
Proceeds from related party deposits
|
125
|
-
|
||||||
Payments of principal on finance leases
|
(46
|
)
|
(28
|
)
|
||||
Net Cash Flows Provided by Financing Activities
|
1,112
|
2,232
|
||||||
Effect of Exchange Rates on Cash
|
(8
|
)
|
5
|
|||||
Net Change in Cash During Period
|
(2,341
|
)
|
(414
|
)
|
||||
Cash at Beginning of Period
|
2,437
|
1,761
|
||||||
Cash at End of Period
|
$
|
96
|
$
|
1,347
|
||||
|
||||||||
Supplemental Information:
|
||||||||
Cash paid for interest
|
$
|
934
|
$
|
-
|
||||
Non-cash Investing and Financing Activities:
|
||||||||
Cashless warrant exercise
|
$
|
2,030
|
$
|
-
|
||||
Conversion of short-term notes payable to equity
|
-
|
264
|
||||||
Conversion of advamces from related parties to equity
|
-
|
2
|
||||||
Additions to right of use assets from new finance lease liabilities
|
-
|
128
|
1. |
Nature of the Business and Basis of Presentation
|
2. |
Going Concern
|
3. |
Summary of Significant Accounting Policies
|
March 31, 2021
|
December 31, 2020
|
|||||||
Accounts Receivable:
|
||||||||
Customer A
|
15
|
%
|
46
|
%
|
||||
Three Months Ended
|
||||||||
March 31, 2021
|
March 31, 2020
|
|||||||
Revenue:
|
||||||||
Customer B
|
n/a
|
66
|
%
|
Three Months Ended
|
||||||||
March 31, 2021
|
March 31, 2020
|
|||||||
Purchases:
|
||||||||
Vendor A
|
55
|
%
|
n/a
|
|||||
Vendor B
|
13
|
%
|
n/a
|
|||||
Vendor C
|
n/a
|
35
|
%
|
|||||
Vendor D
|
n/a
|
22
|
%
|
|||||
Vendor E
|
n/a
|
11
|
%
|
4. |
Loss per Share
|
2021
|
2020
|
|||||||
Weighted average shares outstanding
|
||||||||
Common shares
|
481,619,621
|
296,061,866
|
||||||
Common shares issuable assuming excercise of nominally priced warrants
|
36,870,604
|
-
|
||||||
Weighted average shares outstanding
|
518,490,225
|
296,061,866
|
2021
|
2020
|
|||||||
Common stock options
|
31,864,385
|
34,403,385
|
||||||
Common stock purchase warrants
|
142,265,576
|
8,374,091
|
||||||
Convertible notes payable
|
60,328,907
|
-
|
||||||
Short-term notes payable
|
-
|
2,250,000
|
||||||
Convertible preferred stock
|
-
|
16,071,429
|
||||||
234,458,868
|
61,098,905
|
5. |
Inventory
|
2021
|
2020
|
|||||||
Inventory - finished goods
|
$
|
2,270
|
$
|
2,276
|
||||
Inventory - parts and accessories
|
665
|
680
|
||||||
Total inventory
|
$
|
2,935
|
$
|
2,956
|
6. |
Accrued Expenses
|
2021
|
2020
|
|||||||
Outside services
|
$
|
191
|
$
|
347
|
||||
License fees
|
298
|
336
|
||||||
Board of director’s fees
|
380
|
320
|
||||||
Registration penalties
|
1,055
|
264
|
||||||
Commissions
|
-
|
239
|
||||||
Legal and professional fees
|
139
|
197
|
||||||
Warranty reserve
|
180
|
180
|
||||||
Inventory purchases
|
72
|
91
|
||||||
Other
|
177
|
153
|
||||||
$
|
2,492
|
$
|
2,127
|
7. |
Revenue
|
Three Months Ended March 31, 2021
|
Three Months Ended March 31, 2020
|
|||||||||||||||||||||||
United States
|
International
|
Total
|
United States
|
International
|
Total
|
|||||||||||||||||||
Product
|
$
|
41
|
$
|
212
|
$
|
253
|
$
|
34
|
$
|
41
|
$
|
75
|
||||||||||||
Accessories and parts
|
1,689
|
136
|
1,825
|
63
|
-
|
63
|
||||||||||||||||||
License fees and other
|
33
|
5
|
38
|
1
|
10
|
11
|
||||||||||||||||||
$
|
1,763
|
$
|
353
|
$
|
2,116
|
$
|
98
|
$
|
51
|
$
|
149
|
March 31,
2021
|
December 31,
2020
|
|||||||
Service agreements
|
$
|
63
|
$
|
69
|
||||
Deposit on future equipment purchases
|
125
|
-
|
||||||
Total contract liabilities
|
188
|
69
|
||||||
Less: current portion
|
(32
|
)
|
(32
|
)
|
||||
Non-current contract liabilities
|
$
|
156
|
$
|
37
|
8. |
Debt with Related Parties
|
2021
|
2020
|
Maturity Date
|
Stated Interest
Rate
|
Incremental
Default
Interest
|
|||||||||||||
Convertible promissory notes (HealthTronics), related parties, in default
|
$
|
1,372
|
$
|
1,372
|
In default
|
12.0
|
%
|
+2.0
|
%
|
||||||||
Convertible promissory notes (Stolarski), related parties, in default
|
224
|
224
|
In default
|
12.0
|
%
|
+2.0
|
%
|
||||||||||
Total debt with related parties
|
$
|
1,596
|
$
|
1,596
|
9. |
Debt with Unaffiliated Parties
|
2021
|
2020
|
Maturity Date
|
Stated Interest
Rate
|
Incremental
Payment in
Kind Interest
|
Incremental
Default Interest
|
||||||||||||||||
Senior secured promissory note payable, in default::
|
|||||||||||||||||||||
Principal
|
$
|
15,000
|
$
|
15,000
|
|||||||||||||||||
Debt issuance costs
|
(1,440
|
)
|
(1,520
|
)
|
|||||||||||||||||
Debt discount
|
(2,657
|
)
|
(2,804
|
)
|
|||||||||||||||||
10,903
|
10,676
|
In default
|
12.25
|
%
|
+3.00
|
%
|
+5.00
|
%
|
|||||||||||||
Convertible promissory note payable, in default
|
4,000
|
4,000
|
In default
|
12.00
|
%
|
n/a
|
+5.00
|
%
|
|||||||||||||
SBA loan #1
|
464
|
464
|
May 28, 2022
|
1.00
|
%
|
n/a
|
n/a
|
||||||||||||||
SBA loan #2
|
1,033
|
-
|
February 20, 2026
|
1.00
|
%
|
n/a
|
n/a
|
||||||||||||||
|
16,400
|
15,140
|
|||||||||||||||||||
Less: current maturities including notes in default
|
(15,367
|
)
|
(14,997
|
)
|
|||||||||||||||||
Debt with unafffiliated parties, long-term
|
$
|
1,033
|
$
|
143
|
10. |
Warrants
|
Warrant class
|
Outstanding
December 31,
2020
|
Exercised
|
Outstanding
March 31,
2021
|
Exercise
price/share
|
Expiration
date
|
||||||||||||
Class E Warrants
|
141,091,485
|
-
|
141,091,485
|
$
|
0.25
|
August 2023
|
|||||||||||
Class O Warrants
|
909,091
|
-
|
909,091
|
0.11
|
January 2022
|
||||||||||||
Class P Warrants
|
265,000
|
-
|
265,000
|
0.20
|
June 2024
|
||||||||||||
LGH Warrant
|
35,000,000
|
(11,400,000
|
)
|
23,600,000
|
0.01
|
June 2025
|
|||||||||||
NH Expansion Warrant
|
13,091,160
|
-
|
13,091,160
|
0.01
|
August 2030
|
||||||||||||
Total
|
190,356,736
|
(11,400,000
|
)
|
178,956,736
|
11. |
Warrant Liabilities
|
Warrants
Outstanding
|
Fair Value
per Share
|
Fair Value
|
||||||||||
Balance December 31, 2020
|
48,091,160
|
$
|
0.18
|
$
|
8,855,379
|
|||||||
Cashless exercise of LGH Warrants
|
(11,400,000
|
)
|
0.18
|
(2,030,025
|
)
|
|||||||
Gain on remeasurement of warrant liability
|
(634,672
|
)
|
||||||||||
Balance March 31, 2021
|
36,691,160
|
$
|
0.17
|
$
|
6,190,682
|
Black Scholes option pricing model
|
March 31,2021
|
December 31, 2020
|
|||||||
Exercise Price(1)
|
$
|
0.01
|
$
|
0.01
|
|||||
Warrant Expiration Date (1)
|
August 6, 2030
|
August 6, 2030
|
|||||||
Interest Rate (annual) (2)
|
0.70
|
%
|
0.65
|
%
|
|||||
Volatility (annual) (3)
|
145.04
|
%
|
143.94
|
%
|
|||||
Time to Maturity (Years)
|
9.4
|
9.6
|
|||||||
Calculated fair value per share
|
$
|
0.1700
|
$
|
0.1891
|
Black Scholes option pricing model
|
March 31, 2021
|
December 31, 2020
|
|||||||
Exercise Price(1)
|
$
|
0.01
|
$
|
0.01
|
|||||
Warrant Expiration Date (1)
|
June 5, 2025
|
June 5, 2025
|
|||||||
Interest Rate (annual) (2)
|
0.37
|
%
|
0.36
|
%
|
|||||
Volatility (annual) (3)
|
100.16
|
%
|
99
|
%
|
|||||
Time to Maturity (Years)
|
4.2
|
4.4
|
|||||||
Calculated fair value per share
|
$
|
0.1680
|
$
|
0.1823
|
(1) |
Based on the terms provided in the warrant agreement to purchase common stock of the Company dated August 6, 2020.
|
(2) |
Interest rate for U.S. Treasury Bonds, as of each presented period ending date, as published by the U.S. Federal Reserve.
|
(3) |
Based on the historical daily volatility of the Company as of each presented period ending date.
|
12. |
Leases
|
March 31, 2021
|
December 31, 2020
|
|||||||||||||||||||||||
Operating
Leases
|
Financing
Leases
|
Total
|
Operating
Leases
|
Financing
Leases
|
Total
|
|||||||||||||||||||
Right of use assets
|
$
|
725
|
$
|
644
|
$
|
1,369
|
$
|
725
|
$
|
644
|
$
|
1,369
|
||||||||||||
Less: Accumulated amortization
|
(396
|
)
|
(288
|
)
|
(684
|
)
|
(339
|
)
|
(235
|
)
|
(574
|
)
|
||||||||||||
Right of use assets, net
|
$
|
329
|
$
|
356
|
$
|
685
|
$
|
386
|
$
|
409
|
$
|
795
|
||||||||||||
Lease liabilities
|
$
|
352
|
$
|
381
|
$
|
733
|
$
|
415
|
$
|
427
|
$
|
842
|
||||||||||||
Less: current portion
|
(214
|
)
|
(200
|
)
|
(414
|
)
|
(257
|
)
|
(194
|
)
|
(451
|
)
|
||||||||||||
Lease Liabilities
|
$
|
138
|
$
|
181
|
$
|
319
|
$
|
158
|
$
|
233
|
$
|
391
|
2021
|
2020
|
|||||||
Finance lease costs:
|
||||||||
Amortization of right-of-use assets
|
$
|
53
|
$
|
41
|
||||
Interest on lease liabilities
|
13
|
12
|
||||||
Operating lease costs
|
83
|
52
|
||||||
Total lease costs
|
$
|
149
|
$
|
105
|
2021
|
2020
|
|||||||
Cash paid for amouonts included in measurement of lease liabilities:
|
||||||||
Operating cash flows from finance leases
|
$
|
(59
|
)
|
$
|
(40
|
)
|
||
Operating cash flows from operating leases
|
$
|
(83
|
)
|
$
|
(55
|
)
|
Amount
|
||||
Year ending December 31,
|
||||
2021 (remainder of year)
|
$
|
210
|
||
2022
|
94
|
|||
2023
|
65
|
|||
2024
|
8
|
|||
2025
|
3
|
|||
Total lease payments
|
380
|
|||
Less: Present value adjustment
|
(28
|
)
|
||
Lease liability
|
$
|
352
|
Amount
|
||||
Year ending December 31,
|
||||
2021 (remainder of year)
|
$
|
176
|
||
2022
|
200
|
|||
2023
|
18
|
|||
Total lease payments
|
394
|
|||
Less: Present value adjustment
|
(13
|
)
|
||
Lease liability
|
$
|
381
|
13. |
Contingencies
|
14. |
Related Party Transactions
|
15. |
Income Taxes
|
16. |
Subsequent Events
|
Item 2. |
Item 3. |
Item 4. |
|
• |
The Company lacks expertise and resources to analyze and properly apply U.S. GAAP to complex and non-routine transactions such as complex financial instruments and derivatives and complex sales distribution
agreements.
|
|
• |
The Company lacks internal resources to analyze and properly apply U.S. GAAP to accounting for financial instruments included in service agreements with select vendors.
|
|
• |
The Company has failed to design and implement controls around all of its accounting and IT processes and procedures and, as such, it believes that all of its accounting and IT processes and procedures need
to re-designed and tested for operating effectiveness.
|
Item 1. |
Item 1A. |
Item 2. |
Item 3. |
Item 4. |
Item 5. |
Exhibit No.
|
Description
|
Promissory Note by and between SANUWAVE Health, Inc. and Northeast Bank, dated February 20, 2021.
|
|
Factoring Agreement by and between SANUWAVE Health, Inc. and Goodman Capital Finance dated June 17, 2021.
|
|
Future Receivables Agreement by and between GCF Resources LLC and SANUWAVE, Inc. dated September 27, 2021.
|
|
Promissory Note by and between SANUWAVE Health, Inc. and A. Michael Stolarski, dated October 27, 2021.
|
|
Promissory Note by and between SANUWAVE Health, Inc. and NightWatch Capital Advisors, LLC, dated October 27, 2021.
|
|
Letter Agreement Amendment dated May 14, 2021 to the April 20, 2021 Securities Purchase Agreement by and between the Company and Leviston Resources, LLC
|
|
Rule 13a-14(a)/15d-14(a) Certification of the Principal Executive Officer.
|
|
Rule 13a-14(a)/15d-14(a) Certification of the Chief Financial Officer.
|
|
Section 1350 Certification of the Principal Executive Officer.
|
|
Section 1350 Certification of the Chief Financial Officer.
|
|
101.INS*†
|
XBRL Instance.
|
101.SCH*†
|
XBRL Taxonomy Extension Schema.
|
101.CAL*†
|
XBRL Taxonomy Extension Calculation.
|
101.DEF*†
|
XBRL Taxonomy Extension Definition.
|
101.LAB*†
|
XBRL Taxonomy Extension Labels.
|
101.PRE*†
|
XBRL Taxonomy Extension Presentation.
|
SANUWAVE HEALTH, INC.
|
|
Dated: December 13, 2021
|
By: /s/ Kevin A. Richardson, II
|
Name: Kevin A. Richardson, II
|
|
Title: Chief Executive Officer
|
Signatures
|
Capacity
|
Date
|
||
By: /s/ Kevin A. Richardson, II
Name: Kevin A. Richardson, II
|
Chief Executive Officer and Chairman of the Board of Directors
(principal executive officer)
|
December 13, 2021
|
||
By: /s/ Lisa E. Sundstrom
Name: Lisa E. Sundstrom
|
Chief Financial Officer (principal financial and accounting officer)
|
December 13, 2021
|
SBA Loan#
|
1964668500
|
||
SBA Loan Name
|
Paycheck Protection Program Loan
|
||
Date
|
02/20/2021
|
||
Loan Amount
|
$ 1033005.0
|
||
Interest Rate
|
Fixed rate equal to one percent (1.00%) per annum
|
||
Borrower
|
SANUWAVE, Inc.
|
||
Lender
|
Northeast Bank, a banking corporation organized under the laws of the State of Maine
|
1. |
PROMISE TO PAY:
|
2. |
DEFINITIONS:
|
3. |
PAYMENTTERMS:
|
|
A. |
Maturity Date: Unless forgiven in writing or otherwise modified in compliance with the terms of the PPP or other applicable
SBA requirements, this Note matures five (5) years from the date of disbursement of the Loan (the "Maturity Date").
|
|
B. |
Interest Rate: Principal amounts outstanding under this Note shall bear interest at a rate per annum (the "Interest Rate")
equal to 1.00%. All computations of interest hereunder shall be made on the basis of a year of 365/365 and the actual number of days elapsed. Interest shall begin to accrue on the Disbursement Date.
|
|
C. |
Use of Proceeds: Borrower shall use the proceeds of this Loan only for eligible expenses under the terms of the PPP.
|
|
D. |
Payment: Borrower must pay principal and interest payments (as calculated by Lender using an
amortization schedule based on the number of months remaining in the term of the Loan at the end of the Deferment Period through the Maturity Date and a 1.00% interest rate, accounting for any Deferred Interest) commencing on the
first Payment Date in the month immediately following the Deferment Period and continuing monthly on each Payment Date thereafter and ending on the Maturity Date. Payments must be made on the same day as the Disbursement Date (such
date hereinafter the "Payment Date") in the months they are due and must be made in US dollars. Borrower's repayment obligation will be reduced by the amount of any loan forgiveness granted under the terms of the PPP. While no payments are due on this Loan for the Deferment Period, interest will continue to accrue during the Deferment Period (such interest the "Deferred Interest"). All
outstanding principal and accrued and unpaid interest shall be due and payable on the Maturity Date. Lender will apply each installment payment first to pay Deferred Interest, then to interest accrued to the day Lender received
the payment, then to principal. Any payment received after default, demand or acceleration shall be applied in accordance with SBA servicing guidelines.
|
|
E. |
Deferment Period: No payments are due
on this Loan for the earlier of (i) the period from the Disbursement Date to the month that the SBA determines loan forgiveness, provided the forgiveness application was made within ten (10) months of the end of the loan forgiveness
covered period, or (ii) ten (10) months from end of the loan forgiveness covered period in the event no application for forgiveness is made (or such other period as amended by further PPP guidance issued by the SBA). Interest will
continue to accrue during the Deferment Period.
|
|
F. |
Loan Prepayment: Notwithstanding any provision in this Note to the contrary, Borrower may prepay this Note at any time
without penalty.
|
|
G. |
Loan Forgiveness: Borrower may apply to Lender for forgiveness of the amount due on this Loan in an amount in accordance
with the requirements of the Paycheck Protection Program.
|
|
H. |
Manner of Payment: All payments of principal and interest shall be made in US dollars on the date on which such payment is
due. Such payments shall be made by ACH, cashier's check, certified check, or wire transfer of immediately available funds to the holder of the Note ("Noteholder"). For purposes of this Note, the term Noteholder shall refer to the
original Noteholder, or any assignee.
|
4. |
DEFAULT:
|
|
A. |
Fails to do anything required by this Note and other Loan Documents;
|
|
B. |
Defaults on any other government guaranteed loan;
|
|
C. |
Does not disclose, or anyone acting on their behalf does not disclose, any material fact to Lender or SBA;
|
|
D. |
Makes, or anyone acting on their behalf makes, a materially false or misleading representation to Lender or SBA;
|
|
E. |
Reorganizes, merges, consolidates, or otherwise changes ownership or business structure without Lender's prior written consent;or
|
|
F. |
Becomes the subject of a civil or criminal action that that impacts Borrower's eligibility under PPP.
|
5. |
LENDER'S RIGHTS IF THERE IS A DEFAULT:
|
|
A. |
Require immediate payment of all {non-forgiven} amounts owing under this Note;
|
|
B. |
Collect all amounts owing from any Borrower; or
|
|
C. |
File suit and obtain judgment.
|
6. |
LENDER'S GENERAL POWERS:
|
|
A. |
Incur expenses to collect amounts due under this Note and enforce the terms of this Note or any other Loan Document. If Lender incurs any collection-related expenses, it
may demand immediate repayment from Borrower or add the expenses to the principal balance;
|
|
B. |
Release anyone obligated to pay this Note; and
|
|
C. |
Take any action necessary to collect amounts owing on this Note.
|
7. |
GOVERNING LAW; WHEN FEDERAL LAW APPLIES:
|
8. |
SUCCESSORS AND ASSIGNS; ASSIGNMENT:
|
9. |
GENERAL PROVISIONS:
|
|
A. |
All individuals and entities signing this Note are jointly and severally liable.
|
|
B. |
Borrower waives all suretyship defenses.
|
|
C. |
Borrower must sign all documents necessary at any time to comply with the Loan Documents.
|
|
D. |
Lender may exercise any of its rights separately or together, as many times and in any order it chooses. Lender may delay or forgo enforcing any of its rights without
giving up any of them.
|
|
E. |
Borrower may not use an oral statement of Lender or SBA to contradict or alter the written terms of this Note. No term of this Note may be waived, modified, or amended,
except by an instrument in writing signed by the Borrower and the Lender, unless the SBA permits otherwise. Any waiver of the terms hereof shall be effective only in the specific instance and for the specific purposes given.
|
|
F. |
If any term or provision of this Note is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or un enforceability shall not affect any
other term or provision of this Note or render such term or provision invalid or unenforceable in any other jurisdiction.
|
|
G. |
To the extent allowed by law, Borrower waives all demands and notices in connection with this Note, including presentment, demand, protest, and notice of dishonor.
|
10. |
NON-RECOURSE:
|
11. |
INDEMNIFICATION: The Borrower will indemnify and hold harmless Lender and any Noteholder (and their respective employees, directors, agents, affiliates and
representatives) from and against any cost, loss or liability including interest, penalties, reasonable attorneys' fees and expenses resulting from the Borrower's misrepresentation in the application for this Loan or otherwise or breach of
warranty, default or breach of any covenant in this Note.
|
12. |
NOTICES. All notices and other communications relating to this Note shall be in writing and shall be deemed given upon the first to occur of (a) deposit with overnight
courier service, properly addressed and shipping prepaid; (b) transmittal by e-mail properly addressed (with written acknowledgement from the intended recipient such as "return receipt requested" function, return e-mail, or other written
acknowledgment); or (c) actual receipt by an employee or agent of the other party. Notices hereunder shall be sent to the following addresses, or to such other address as such party shall specify in writing:
|
Name : SANUWAVE, Inc.
Phone Number: (678) 549-0449
|
Address: 3360 Martin Farm Rd., Ste 100 ,Suwanee, GA, 30(
Attention: Lisa Sundstrom
E-Mail: lisa.sundstrom@sanuwave.com
|
Name:
Northeast Bank
Phone: 800-284-5989
|
Address: PO Box 171769, Boston, MA 02117
Attention: Loan Servicing Department
E-Mail: sbaloans@northeastbank.com
|
13. |
REPRESENTATIONS AND WARRANTIES. The Borrower represents and warrants to the Lender as follows:
|
14. |
STATE-SPECIFIC PROVISIONS. None
|
15. |
INTEGRATION. This Note constitutes the entire contract between the Borrower and the Lender with respect to the subject matter hereof and supersedes previous agreements
and understanding, oral or written, with respect thereto.
|
16. |
CONSENT TO USE ELECTRONIC SIGNATURE. In order to receive the Loan amount, the Lender must provide the Borrower with certain disclosures required by law. By submitting
the Borrower's application and agreeing to the terms of this Note, which the Borrower collectively adopts as its electronic signature, the Borrower consents and agrees that: (i) the Lender and any Noteholder can provide all disclosures
required by law and other information about the Borrower's legal rights and duties to the Borrower electronically, including by e-mail, a website portal or mobile phone application; (ii) the Borrower's electronic signature on agreements and
documents has the same effect as if the Borrower signed them in ink and is evidence of the Borrower's intention to be bound by this Note; (iii) Electronic disclosures have the same meaning and effect as if the Borrower were provided paper
disclosures; (iv) Disclosures are considered received by the Borrower within 24 hours of the time posted to Lender's or any Noteholders website, or within 24 hours of the time emailed to the Borrower unless the Lender or Noteholder receives
notice that the email was not delivered; (v) Lender or the Noteholder reserves the right to cancel this electronic disclosure service, change the terms of use of this service or send disclosures in paper form at any time; (vi) the Lender or
Noteholder is responsible for sending notice of the disclosures to the Borrower electronically, but Lender or Noteholder are not responsible for any delay or failure in the Borrower's receipt or review of the email notices. The Borrower
agrees and confirms that the Borrower has access to the necessary equipment to receive, access and print any disclosures that may be provided in electronic form. The Borrower will not seek to withdraw the Borrower's consent for electronic
signature and disclosures while the Borrower has an outstanding Loan balance.
|
17. |
NO, WAIVER; CUMULATIVE REMEDIES. No failure by Lender or any subsequent Noteholder to exercise and no delay in exercising any right, remedy, or power hereunder shall
operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, or power hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, or power. The rights, remedies, and
powers herein provided are cumulative and not exclusive of any other rights, remedies, or powers provided by law.
|
18. |
COUNTERPARTS. This Note and any amendments, waivers, consents, or supplements hereto may be executed in counterparts, each of which shall constitute an original, but
all of which taken together shall constitute as single contract.
|
19. |
THIRD-PARTY BENEFICIARY. Any assignee of this Note shall be deemed to be a third-party beneficiary to this Note and is entitled to the rights and benefits hereunder and
may enforce the provisions hereof as if they were a party hereto.
|
20. |
ERRORS AND OMISSIONS; COOPERATION. The undersigned Borrower for and in consideration of the Lender funding the closing of this Loan agrees, if requested by Lender or its
assignees, to fully cooperate and adjust for clerical errors, any or all Loan closing documentation if deemed necessary or desirable in the reasonable discretion of the Lender or its assignees. Borrower shall furnish the Lender with such
other information as the Lender may reasonably request from time to time, including but not limited to any documentation necessary to comply with the terms of the PPP.
|
21. |
DISBURSEMENT. The undersigned hereby authorizes the Lender to disburse the entire amount of the Loan proceeds of the Note to Borrower.
|
22. |
BORROWER CERTIFICATION. Borrower understands, acknowledges and agrees that Lender is relying solely on Borrower's representations, warranties,
certifications, confirmations or other statements of, and information from, the Borrower and/or any of its affiliates, officers, directors, owners, principals, agents, and/or controlling persons as to the Borrower, its business or
activities, its eligibility for the proposed Loan, its use of the proceeds or any other benefits of the Loan, the existence of any hardship or other condition, or any other matters of compliance with the PPP or SBA requirements without
limitation or without Lender's examination of any other information not included in the Borrower's Loan application which may be in Borrower's possession. Borrower
hereby recertifies all certifications made by Borrower in its Loan application.
|
23. |
EQUAL EMPLOYMENT OPPORTUNITY. Borrower hereby acknowledges the receipt of a copy of the Equal Employment Opportunity Poster (SBA Form 722) and will display such poster
at Borrower's place of business where it is clearly visible to employees, job applicants, and the general public.
|
By:
|
/s/ Lisa Sundstrom |
|
Name: | Lisa Sundstrom | |
Title: | Chief Financial Officer |
By
|
|
|
Name
|
||
Title |
Attention: |
|
Fax No:
|
(972) 243-6285
|
Email:
|
|
By:
|
/s/ Kevin Richardson, II |
Name:
|
Kevin Richardson, II | |
Title: |
CEO
|
By:
|
/S/ Lisa Sundstrom |
Name:
|
Lisa Sundstrom | |
Title: |
CFO
|
By:
|
/s/ Kevin Richardson, II |
Name:
|
Kevin Richardson, II | |
Title: | President |
By:
|
/s/ Lisa Sundstrom |
Name:
|
Lisa Sundstrom | |
Title: | Secretary |
Reserve
Percentage:
|
13.75%
|
||
Contract Rate:
|
NA
|
||
Eligibility Period
|
With respect to any Account, the earlier of 46 days from the original due date thereof or 90 days from the invoice date thereof.
|
||
Initial Term:
|
I month, commencing upon the Effective Date.
|
||
Renewal Term:
|
I month.
|
||
Facility
Maximum:
|
$3,000,000
|
||
Fees:
|
(a) Initial Commissions. With respect to each Account of Client that is at any time included in the
Formula Amount, Client shall pay to Goodman a commission (with respect to each Account, the "Initial Commission") equal to 1.25% multiplied
by the gross amount of such Account. The Initial Commission for an Account shall be due and payable on the Funding Date for such Account.
(b) Additional Commissions. In the event an Account remains unpaid (in whole or in part) on the 30th day following the Funding Date, Client
shall pay to Goodman, on such 30th day and on each I day thereafter
that such Account remains unpaid, an additional
commission (with respect to each Account, the "Additional Commission") equal to 0.04% multiplied by
the gross amount of such Account as of the Funding Date. For purposes of determining Additional
Commissions, an Account shall be deemed to remain unpaid until the Settlement Date of such Account.
(c) Misdirection Fee. Goodman may charge to Client a misdirected payment fee in the amount of fifteen percent (15%) of the amount of any check, remittance
or other item of payment constituting a payment of an
Account which is received by an Obligor and not deposited into the Collection Account on the next Business Day following receipt by such Obligor.
|
on request of Goodman:
|
(a)
|
such other information as Goodman may request from time to time.
|
Merchant's Legal Name: SANUWAVE, INC.
DBA Name: SANUWAVE
Legal Entity: Corporation
Address: 3360 MARTIN FARM RD #100
|
City: SUWANEE
|
State: GA
|
Zip: 30024
|
Purchase Price
$1,000,000.00
|
Specified Percentage
10%
|
Estimated Daily Amount
$11,834.00
|
Receipts Purchased Amount
$1,420,000.00
|
MERCHANT
|
|||||
BY: KEVIN A RICHARDSON II
|
X
|
/s/ KEVIN A RICHARDSON II |
|
||
|
(SIGNATURE)
|
9/27/2021
|
|||
CEO #1: KEVIN A RICHARDSON II
|
X
|
/s/ KEVIN A RICHARDSON II | |||
|
(SIGNATURE)
|
(DATE)
|
|||
CEO#2:
|
X
|
|
|||
|
|
(DATE)
|
|||
GCF Resources LLC
|
(SIGNATURE)
|
||||
BY:
|
X
|
|
|||
(COMPANY OFFICER)
|
(SIGNATURE)
|
|
|
|
Merchant's Legal Name: SANUWAVE, INC.
Address: 3360 MARTIN FARM RD #100
Federal Tax ID#: 20-3198616
|
DBA Name: SANUWAVE
City: SUWANEE
|
State: GA
|
Zip: 30024
|
MERCHANT
|
|||||
|
|||||
BY: KEVIN A RICHARDSON II
|
X
|
/s/ KEVIN A RICHARDSON II | |||
(SIGNATURE)
|
|||||
CEO #1: KEVIN A RICHARDSON II
|
X
|
/s/ KEVIN A RICHARDSON II |
9/27/2021
|
||
(SIGNATURE)
|
(DATE)
|
||||
(SOCIAL SECURITY#)
|
|||||
|
(DRIVERS LICENSE)
|
||||
CEO#2:
|
X
|
|
|||
|
(SIGNATURE)
|
(DATE)
|
|||
(SOCIAL SECURITY#)
|
|||||
|
(DRIVERS LICENSE)
|
• |
There has been no promise of additional capital in 30 days from funding by GCF Resources LLC or any ISO (broker)
|
|
o |
Our policy is that merchants can seek additional capital from us when they have paid 50% of the Receipts Purchased Amount.
|
• |
There has not been and will not be any contact from third party debt companies regarding this Future Receivables Agreement dated
|
/s/ KEVIN A RICHARDSON II
|
9/27/2021 | ||
Signature
|
|
Date |
U.S. $150,000.00
|
Dated: October 27, 2021
|
If to the Lender:
|
[_______________]
|
||
[_______________] | |||
[_______________] | |||
[_______________] | |||
|
|||
If to the Borrower:
|
[_______________] | ||
|
[_______________] | ||
[_______________] | |||
[_______________] |
|
SANUWAVE HEALTH, INC. | ||
|
|
|
|
|
By | /s/ Kevin Richardson | |
|
|
Name:
|
Kevin Richardson
|
|
|
Title: |
CEO
|
U.S. $25,000.00
|
Dated: October 27, 2021
|
If to the Lender:
|
[_______________]
|
||
[_______________] | |||
[_______________] | |||
[_______________] | |||
|
|||
If to the Borrower:
|
[_______________] | ||
|
[_______________] | ||
[_______________] | |||
[_______________] |
|
SANUWAVE HEALTH, INC. | ||
|
|
|
|
|
By | /s/ Kevin Richardson | |
|
|
Name:
|
Kevin Richardson
|
|
|
Title: |
CEO
|
Sanuwave Health Inc.
|
May14, 2021
|
3360 Martin Farm Road
|
|
Suite 100
|
|
Suwanee, GA 30024
|
|
Attention: Kevin A. Richardson II
|
|
Re: |
Securities Purchase Agreement/Future Advance Convertible Promissory Note
|
|
a. |
The Note, the SPA and each of the Transaction Documents are hereby amended by removing each reference to "$3,402,000" therein and replacing the same with "$4,217,217".
|
|
b. |
Section 3(c)(iii) of the Note is hereby amended by deleting the first sentence thereof in its entirety and replacing it with the following:
|
|
c. |
Article 4 of the SPA is hereby amended by adding at the end thereof the following new Section 4.25:
|
|
Very truly yours,
|
||
|
|
||
|
LEVISTON RESOURCES LLC
|
||
|
|
||
|
By:
|
/s/ R. Rogol |
|
Name:
|
R. Rogol |
|
Title:
|
CFO |
ACCEPTED AND AGREED:
|
|
||
|
|
||
SANUWAVE HEALTH, INC.
|
|
||
|
|
||
By:
|
/s/ Kevin A. Richardson II
|
|
|
Name:
|
Kevin A. Richardson II
|
|
Title:
|
Chief Executive Officer
|
|
1. |
I have reviewed this quarterly report on Form 10-Q of SANUWAVE Health, Inc.;
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and
|
d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in
the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the
registrant’s board of directors (or persons performing the equivalent functions):
|
|
a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record,
process, summarize and report financial information; and
|
|
b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: December 13, 2021
|
|
/s/ Kevin A. Richardson II
|
|
Kevin A. Richardson II
|
|
Chief Executive Officer
|
|
(principal executive officer)
|
1. |
I have reviewed this quarterly report on Form 10-Q of SANUWAVE Health, Inc.;
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period covered by this report;
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in this report;
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
|
a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and
|
|
d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in
the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the
registrant’s board of directors (or persons performing the equivalent functions):
|
|
a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record,
process, summarize and report financial information; and
|
|
b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
Date: December 13, 2021
|
|
/s/Lisa E. Sundstrom
|
|
Lisa E. Sundstrom
|
|
Controller and Chief Financial Officer
|
|
(principal financial officer and principal accounting officer)
|
1. |
The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
|
2. |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.
|
Date: December 13, 2021
|
|
/s/ Kevin A. Richardson II
|
|
Kevin A. Richardson II
|
|
Chief Executive Officer
|
|
(principal executive officer)
|
1. |
The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
|
2. |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.
|
Date: December 13, 2021
|
|
/s/ Lisa E. Sundstrom
|
|
Lisa E. Sundstrom
|
|
Controller and Chief Financial Officer
|
|
(principal financial officer and principal accounting officer)
|